share_log

Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Lowers Price Target to $42

Benzinga ·  Oct 25, 2023 15:38

Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and lowers the price target from $43 to $42.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment